Do you want to read an article? Please log in or register.
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Related content
Diabetes - GeneralType 2 Diabetes
Alirocumab versus usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Diabetes Obes Metab.
Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S
doi: 10.1111/dom.13257.
Diabetes - GeneralLipids
Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials
Diabetes Obes Metab.
Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, Letierce A, Leiter LA
doi: 10.1111/dom.13384.
COMMENTED
Type 2 Diabetes
Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB
doi: 10.1016/S2213-8587(21)00174-1
Type 2 Diabetes
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial
Lancet Diabetes Endocrinol.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y, PIONEER 9 investigators.
doi: 10.1016/S2213-8587(20)30075-9.
Further Publications
Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial
Diabetes Obes Metab
Lu J, Fu L, Li Y, Geng J, Qin L, Ping L, Zheng H, Sun Z, Li Y, Zhang L, Sun Y, Chen D, Qin G, Weiping L, Guo Y, Zhang Y, Liu H, Zhang T, Zou J
doi: 10.1111/dom.14314
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Int J Cardiol.
Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B
doi: 10.1016/j.ijcard.2016.08.273.
COMMENTED
Type 2 Diabetes
Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
Lancet Diabetes Endocrinol.
Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, Thielke D, Viljoen A, McCrimmon RJ
doi: 10.1016/
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Am J Cardiol.
Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, Louie MJ, Raal FJ
doi: 10.1016/
Diabetes - GeneralType 2 DiabetesGlycemic Control
Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial
Diabetes Care.
Jabbour SA, Frìas JP, Hardy E, Ahmed A, Wang H, Öhman P, Guja C
doi: 10.2337/dc18-0680.